{"filing":{"accession_number":"0001493152-26-044381","cik":"0001855485","ticker":"CLDWW","company_name":"Calidi Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-21","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/form8-k.htm"},"events":[{"id":35210,"run_id":32420,"accession_number":"0001493152-26-044381","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Calidi received a notice from NYSE American on September 21, 2026, stating non-compliance with the stockholders' equity continued listing standard (Section 1003(a)(ii)), requiring $4.0 million in equity but the company reported only $3.1 million as of June 30, 2026. The company has until October 21, 2026, to submit a compliance plan or face delisting proceedings by March 21, 2028. This is a clear delisting risk disclosure under Item 3.01.","company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDWW","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":39176,"accession_number":"0001493152-26-044381","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Calidi received a notice from NYSE American on September 21, 2026, stating non-compliance with the stockholders' equity continued listing standard (Section 1003(a)(ii)), requiring $4.0 million in equity but the company reported only $3.1 million as of June 30, 2026. The company has until October 21, 2026, to submit a compliance plan or face delisting proceedings by March 21, 2028. This is a clear delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T21:27:14.281438+00:00","company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDWW","filing_date":"2026-09-25"}]}